Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Chimerix

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 72

Market Cap: $88M

Website

Introduction: Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Clinical Trials

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

Phase 3

Terminated

Conditions: Cytomegalovirus Disease
Kidney Transplant Infection

Interventions: Drug: Valganciclovir
Drug: Brincidofovir

First Posted Date: 2015-05-12

Last Posted Date: 2021-07-16

Lead Sponsor: Chimerix

Target Recruit Count: 6

Registration Number: NCT02439957

Locations: 🇺🇸
St. Vincent Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

Terminated

Conditions: Adenovirus

Interventions: Drug: Brincidofovir

First Posted Date: 2015-04-17

Last Posted Date: 2017-01-09

Lead Sponsor: Chimerix

Target Recruit Count: 100

Registration Number: NCT02420080

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Childrens National Health System, Washinton, District of Columbia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 19 locations

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Phase 2

Withdrawn

Conditions: Ebola Virus

Interventions: Drug: CMX001

First Posted Date: 2014-10-22

Last Posted Date: 2015-02-02

Lead Sponsor: Chimerix

Registration Number: NCT02271347

The Chimerix CMX001 Registry

Terminated

Conditions: Outcomes
Survival Rates

Interventions: Drug: CMX001

First Posted Date: 2014-06-19

Last Posted Date: 2019-05-17

Lead Sponsor: Chimerix

Target Recruit Count: 550

Registration Number: NCT02167685

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
St. Vincent Medical Center, Los Angeles, California, United States
🇺🇸
Children's Hospital of LA, Los Angeles, California, United States

and more 48 locations

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

Phase 3

Completed

Conditions: Adenovirus Infection

Interventions: Drug: Brincidofovir

First Posted Date: 2014-03-14

Last Posted Date: 2021-08-13

Lead Sponsor: Chimerix

Target Recruit Count: 201

Registration Number: NCT02087306

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford Children's Hospital, Palo Alto, California, United States

and more 30 locations

A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Dociparstat sodium

First Posted Date: 2014-02-06

Last Posted Date: 2023-02-21

Lead Sponsor: Chimerix

Target Recruit Count: 12

Registration Number: NCT02056782

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Phase 1

Withdrawn

Conditions: Advanced Colorectal Cancer
Advanced Triple-negative Breast Cancer
Advanced Non-small Cell Lung Cancer
Advanced Glioblastoma

Interventions: Drug: ONC201

First Posted Date: 2014-01-16

Last Posted Date: 2021-04-30

Lead Sponsor: Chimerix

Registration Number: NCT02038699

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

Early Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ODSH

First Posted Date: 2013-04-30

Last Posted Date: 2021-11-10

Lead Sponsor: Chimerix

Target Recruit Count: 10

Registration Number: NCT01843634

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

Phase 3

Completed

Conditions: CMV

Interventions: Other: Placebo
Drug: Brincidofovir

First Posted Date: 2013-01-16

Last Posted Date: 2021-07-21

Lead Sponsor: Chimerix

Target Recruit Count: 452

Registration Number: NCT01769170

Locations: 🇺🇸
University of California, San Diego-Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado, Denver, Colorado, United States

and more 40 locations

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Phase 2

Terminated

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Nab paclitaxel
Drug: Gemcitabine
Drug: Dociparstat

First Posted Date: 2011-10-28

Last Posted Date: 2022-06-06

Lead Sponsor: Chimerix

Target Recruit Count: 60

Registration Number: NCT01461915

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Disney Family Cancer Center, Burbank, California, United States
🇺🇸
Marin Cancer Care, Greenbrae, California, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy